<sup>18</sup>F-FDG PET/CT定量参数与DLBCL预后转归的关联性及预测价值分析

doi:10.3969/j.issn.1006-6233.2025.06.13

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (1435 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the correlation and predictive value of quantitative parameters of ¹⁸F-fluorodeoxyglucose positron-emission tomography compared with computed tomography (¹⁸F-FDG PET/CT) with the prognosis and outcome of diffuse large B-cell lymphoma (DLBCL). Methods: A total of 200 DLBCL patients from The First Affiliated Hospital of Xinjiang Medical University from May 2020 to May 2022 were selected. All patients underwent ¹⁸F-FDG PET/CT examination to obtain quantitative parameters. After a 2-year follow-up, patients were divided into a poor prognosis group and a good prognosis group according to their prognosis. The general information and ¹⁸F-FDG PET/CT quantitative parameters [maximum standard uptake value (SUV_max), average standard uptake value (SUV_mean), maximum metabolic tumor volume (MTV_max), total metabolic tumor volume (MTV_sum), maximum glycolysis (TLG_max), total glycolysis (TLG_sum), maximum diameter of the largest lesion (D_max)] were compared between the two groups. Logistic regression analysis was used to analyze the factors affecting poor prognosis. A conventional logistic prediction model was established based on conventional influencing factors. A new logistic prediction model was established by combining conventional influencing factors with quantitative parameters of ¹⁸F-FDG PET/CT. The predictive value of the two logistic prediction models was analyzed using the receiver operating characteristic (ROC) curve. Results: Among the 192 patients who completed follow-up, 81 patients had a poor prognosis (42 relapsed, 23 progressed, and 16 died), and 111 patients had a good prognosis. The proportion of Ann-Arbor stage Ⅲ~Ⅳ, the proportion of International Prognostic Index (IPI) score ≥4, the lactate dehydrogenase/albumin ratio (LAR), and the MTV_max, MTV_sum, TLG_max, TLG_sum, D_max in the poor prognosis group were higher than those in the good prognosis group, while the albumin/fibrinogen ratio (AFR) was lower than that in the good prognosis group, with statistically significant differences (P<0.05). Logistic regression analysis showed that Ann-Arbor staging (OR=2.129, 95%CI: 1.426~3.180), IPI (OR=2.640, 95%CI: 1.731~4.025), AFR (OR=0.383, 95%CI: 0.267~0.549), LAR (OR=1.420, 95%CI: 1.143~1.765), MTV_max (OR=1.503, 95%CI: 1.206~1.873), MTV_sum (OR=1.445, 95%CI: 1.185~1.761), TLG_max (OR=1.487, 95%CI: 1.193~1.854), TLG_sum (OR=1.455, 95%CI: 1.175~1.802), D_max (OR=1.519, 95%CI: 1.220~1.891) were all factors affecting the poor prognosis of DLBCL patients (P<0.05). A logistic prediction model was constructed, and ROC analysis showed that the area under the curve (AUC) of the new model for predicting poor prognosis in DLBCL patients was 0.941 (95%CI: 0.897~0.970), which was superior to the predictive performance of conventional models (P<0.05). Conclusion: The ¹⁸F-FDG PET/CT quantitative parameters of MTV_max, MTV_sum, TLG_max, TLG_sum, and D_max are all factors influencing the poor prognosis of patients with DLBCL, and the combination of them with conventional indices can significantly increase the predictive value of the risk of poor prognosis, which can be used as a new protocol for clinical prediction of prognosis and guide clinical decision-making.

Key words： Diffuse large B-cell lymphoma ¹⁸F-fluorodeoxyglucose Positron-emission tomography compared with computed tomography Quantitative parameters Prognostic outcome

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yubin
	ZHANG Qizhou
	LI Xiaohong

Cite this article:

LI Yubin,ZHANG Qizhou,LI Xiaohong. Correlation and Predictive Value Analysis of ¹⁸F-FDG PET/CT Quantitative Parameters with the Prognosis and Outcomes of DLBCL[J]. HeBei Med, 2025, 31(6): 947-953.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2025.06.13 OR http://www.hbyxzzs.cn/EN/Y2025/V31/I6/947

[1] Shi YF,Xu Y,Shen HF,et al.Advances in biology,diagnosis and treatment of DLBCL[J].Ann Hematol,2024,103(9):3315-3334.
[2] Evangelista L,Crimi F,Visentin A,et al.[18F] FDG PET/CT and PET/MR in patients with adrenal lymphoma:a systematic review of literature and a collection of cases[J].Curr Oncol,2022,29(10):7887-7899.
[3] Sathyamurthy I,Elangovan I.18F-FDG PET/CT in reclassifying the probable diagnosis of IE-A review[J].Indian Heart,2024,76(1):10-15.
[4] 中华人民共和国国家卫生健康委员会.淋巴瘤诊疗规范(2018年版)[J].肿瘤综合治疗电子杂志,2019,5(4):50-71.
[5] Burggraaff CN,Eertink JJ,Lugtenburg PJ,et al.¹⁸F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma:the HOVON-84 study[J].Nucl Med,2022,63(7):1001-1007.
[6] Haidar M,Kassas M,Chehade F,et al.The role of 18 F-FDG-PET/CT in the management of differentiated thyroid cancer[J].Nucl Med Commun,2023,44(11):1046-1052.
[7] Lodi Rizzini E,Repaci A,Tabacchi E,et al.Impact of ¹⁸F-FDG PET/CT on clinical management of suspected radio-Iodine refractory differentiated thyroid cancer (RAI-R-DTC)[J].Diagnostics (Basel),2021,11(8):1430-1430.
[8] Cartron G,Bachy E,Tilly H,et al.Randomized phase Ⅲ trial evaluating subcutaneous rituximab for the first-line treatment of low-tumor burden follicular lymphoma:results of a LYSA study[J].Clin Oncol,2023,41(19):3523-3533.
[9] Sachpekidis C,Enqvist O,Ulén J,et al.Application of an artificial intelligence-based tool in[18F] FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma[J].Eur Nucl Med Mol Imaging,2023,50(12):3697-3708.
[10] Londalen A,Blakkisrud J,Revheim ME,et al.FDG PET/CT and dosimetric studies of 177lu-lilotomab satetraxetan in a first-in-human trial for relapsed indolent non-hodgkin lymphoma-are we hitting the target[J].Mol Imaging Biol,2022,24(5):807-817.
[11] 朱丽丽,赵汉青,郭莉莉,等.¹⁸F-FDG PET/CT参数预测弥漫大B细胞淋巴瘤中期疗效的应用研究[J].徐州医科大学学报,2022,42(5):369-374.
[12] 任吉莲,崔灵芝,郝小夏,等.miR-21、miR-191与弥漫性大B细胞淋巴瘤患者临床分期的相关性[J].中国实验血液学杂志,2023,31(1):115-119.
[13] Chen HZ,Zhong QF,Zhou Y,et al.Enhancement of the International prognostic index with β2-microglobulin,platelet count and red blood cell distribution width:a new prognostic model for diffuse large B-cell lymphoma in the rituximab era[J].BMC Cancer,2022,22(1):583-583.
[14] 赵金,黄涛,刘鑫.乳酸脱氢酶与白蛋白比值及免疫炎症生物标志物预测转移性结直肠癌预后的临床意义[J].临床肿瘤学杂志,2024,29(3):271-276.